Viral Vector Production in the Integrity iCELLis Single-Use Fixed-Bed Bioreactor, From Bench Scale to Industrial Scale
A. Lennaertz (alenaertz@atmi.com), S. Knowles (sknowles@atmi.com), J.C. Drugmand, J. Castillo, ATMI LifeSciences
Introduction
Wild-type or recombinant viruses used as vaccines and human Gene Therapy vectors are an important development tool in modern medicine. Some have demonstrated high potential such as lentivirus, paramyxovirus and adeno-associated-virus (AAV). These vectors are produced in adherent and suspension cell cultures (e.g. HEK293T, A549, VERO, PER.C6, Sf9) using either transient transfection (e.g PEI, calcium phosphate precipitation) or infection (e.ecombinant viruses) strategies. Most of these processes are currently achieved in static mode on 2-D systems (Roller Bottles, Cell Factories, etc.) or on suspended microcarriers (porous or non-porous). However, these two systems are time-consuming (large numbers of manipulations, preparation of equipment, etc.) and hardly scalable. In regards to prand traceability, Integrity® iCELLis® biory and monitoring of adherent cell cultures.
This post is sponsored by PALL Corporation.